RXB.L Regulatory News (RXB)

Rex Bionics Plc("Rex Bionics" or the "Company")

Results of General Meeting

30 June 2015, Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users and enables robot assisted physiotherapy exercise, today announces that at a General Meeting held earlier today, all resolutions proposed were passed.

Accordingly admission of the 3,541,166 New Ordinary Shares (including 41,166 Additional Fundraising Shares) is expected to take place at 8.00 a.m. on 1 July 2015.

In addition, pursuant to passing of the resolutions, from 1 July 2015, each of the Company's existing 14,289,360 Ordinary Shares of £1 each will be sub-divided and re-designated into one new Ordinary Share of 10 pence and one new Deferred Share of 90 pence in the share capital of the Company. The new Ordinary Shares of 10 pence will have the same ISIN as the existing Ordinary Shares (GB00BLRLQM66). No new certificates will be issued in respect of the re-designated new Ordinary Shares and the existing share certificates in respect of existing Ordinary Shares will be valid and will continue to be accepted as evidence of title for the new Ordinary Shares.

Following admission, the total number of issued Ordinary Shares in the Company will be 17,830,526. The Company does not hold any Ordinary Shares in treasury and therefore this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

The full text of the resolutions can be found in the Notice of the Meeting in the Circular published by the Company on 15 June 2015 and on the Company's website, www.rexbionics.com.

For further information please contact:

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 781 086 6386

Peter Worrall, Chief Financial Officer

+44 (0)1428 645416

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/Giles Balleny

+44 (0) 20 7710 7600

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville

rexbionics@consilium-comms.com

+44 (0) 203 709 5700

About Rex Bionics Plc

Rex Bionics (AIM: RXB) is the AIM-listed pioneer of the REX Robot that enhances the mobility of wheelchair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists.

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits.

REX is used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options.

In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support anticipated demand for both REX products as well as developing the next generation of REX devices, REX 3.

The use of REX in the home is not approved in the United States of America.

For more information please visit, www.rexbionics.com